Managing severe cholesterol and triglyceride levels often requires a lifetime of daily medications, strict diets, and periodic injections. However, a landmark Phase 1 clinical trial led by the Cleveland Clinic suggests a one-time treatment could change that reality.
In the trial, a single infusion of an experimental CRISPR gene-editing therapy called CTX310 successfully cut LDL ("bad") cholesterol and triglycerides by nearly half for a full year.
How the Gene-Editing Therapy Works
The experimental therapy uses CRISPR-Cas9, a gene-editing tool designed to make precise, targeted modifications directly to a patient's DNA.
When delivered as a single intravenous infusion:
- Targeting the Liver: CTX310 travels to the liver cells.
- Disabling ANGPTL3: It selectively deactivates the ANGPTL3 gene, which normally helps regulate fats circulating in the bloodstream.
- Clearing Fats: By switching off this gene, the body can clear out LDL cholesterol and triglycerides far more efficiently.
Promising 12-Month Trial Results
The study followed 15 patients with hard-to-treat lipid disorders that had not responded adequately to standard medications.
Presented at the European Society of Cardiology annual meeting and published in the New England Journal Of Medicine, the 12-month follow-up showed:
- LDL Cholesterol Drop: Participants who received the highest dose experienced an average 52.5% reduction in LDL cholesterol.
- Triglyceride Lowering: The same high-dose group saw a 47.8% drop in triglycerides.
- Lasting Impact: The reductions remained steady throughout the entire 12-month monitoring period.
Importantly, researchers reported no serious safety events or adverse reactions related to the treatment during the one-year follow-up.
The Road Ahead
While these results are a major step forward, researchers emphasize that CTX310 remains in its experimental stages. Because gene editing alters DNA permanently, long-term safety is paramount.
To ensure patient safety, researchers plan to track participants for 15 years, following FDA guidelines for gene-editing therapies, as larger clinical trials continue to evaluate CTX310 in broader patient groups.
